A., Mignion, L., Desmet, C., Gourgue, F., Jonas, J
Tirzepatide doses range from 2.5 mg to 15 mg weekly, whereas semaglutide doses typically max out at 2 mg weekly for diabetes and up to 2.4 mg for weight management
Patel, S., Lee, H., & Martinez, D
An oral semaglutide formulation (Rybelsus) has been approved for treating type 2 diabetes patients and is now in late-stage clinical development for the treatment of obesity
The metabolic peptide market is growing quickly, which means there are lots of possibilities for pharmaceutical developers, original equipment manufacturers (OEMs), and marketing partners who can set up reliable supply chains with quality-certified manufacturers
Behavioural support programmes such as those offered through NHS weight management services can provide structure, accountability, and evidence-based strategies